Pfizer Inc. $PFE Shares Purchased by Dakota Wealth Management

Dakota Wealth Management grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 33.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 348,386 shares of the biopharmaceutical company’s stock after acquiring an additional 87,308 shares during the period. Dakota Wealth Management’s holdings in Pfizer were worth $8,877,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of PFE. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank boosted its stake in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Envestnet Asset Management Inc. grew its position in Pfizer by 7.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 11,195,080 shares of the biopharmaceutical company’s stock worth $271,368,000 after purchasing an additional 792,967 shares in the last quarter. Finally, Delta Investment Management LLC grew its position in Pfizer by 6.7% during the 2nd quarter. Delta Investment Management LLC now owns 9,775 shares of the biopharmaceutical company’s stock worth $237,000 after purchasing an additional 618 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Erste Group raised its earnings estimates for Pfizer, which supports higher forward earnings expectations and helps justify current valuations. Erste Group Bank Increases Earnings Estimates for Pfizer
• Positive Sentiment: Telescope Innovations announced installation of a second Self-Driving Laboratory at Pfizer — a signal that Pfizer is investing in automated R&D platforms that could accelerate drug discovery efficiency (small direct revenue impact but positive for long-term R&D productivity). Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Positive Sentiment: Pfizer appears on dividend-focused stock lists (e.g., The Motley Fool), which can boost demand from income-oriented investors. My 5 Favorite Dividend Stocks to Buy Right Now
• Neutral Sentiment: Pfizer invited the public to listen to CEO Albert Bourla’s presentation at the TD Cowen Health Care Conference on March 2 — an event that could move the stock if management provides new guidance or program updates. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Neutral Sentiment: Coverage pieces (Zacks / Yahoo) note heightened investor attention on PFE; these articles can increase trading interest but don’t by themselves change fundamentals. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Neutrolis appointed former Pfizer R&D chief Mikael Dolsten to its board — notable industry movement but not a direct driver for Pfizer’s near-term results. Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director

Pfizer Stock Up 1.4%

PFE opened at $27.04 on Tuesday. The company has a market capitalization of $153.71 billion, a PE ratio of 19.88 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The business has a 50-day moving average of $25.96 and a 200-day moving average of $25.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.63 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $27.84.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.